CHCarolyn M. Hendrickson

Carolyn M. Hendrickson

*This is an algorithmically generated author record based on publicly available information.

Carolyn M. Hendrickson has a total of 300 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EquiOx

    by Carolyn M. Hendrickson, Michael S. Lipnick, David Chen, Danni Chen, Tyler J. Law, Romain Pirracchio, John R. Feiner, Ella Behnke, Yu (Celine) Chou, Seif Elmankabadi, et al.


  • Top Cited Papers
    Open Access

    Longitudinal multiomic signatures of ARDS and sepsis inflammatory phenotypes identify pathways associated with mortality

    by Narges Alipanah-Lechner, Lucile Neyton, Pratik Sinha, Carolyn Leroux, Kim Bardillon, Sidney A. Carrillo, Suzanna Chak, Olivia Chao, Taarini Hariharan, Carolyn Hendrickson, et al.

    BACKGROUND: Critically ill patients with acute respiratory distress syndrome (ARDS) and sepsis exhibit distinct inflammatory phenotypes with divergent clinical outcomes, but the underlying molecular mechanisms remain poorly understood. These phenotypes, derived from clinical data and protein biomarkers, were associated with metabolic differences in a pilot study. METHODS: We performed integrative multiomics analysis of blood samples from 160 patients with ARDS in the ROSE trial, randomly selecting 80 patients from each latent class analysis–defined inflammatory phenotype (hyperinflammatory and hypoinflammatory) with phenotype probability greater than 0.9. Untargeted plasma metabolomics and whole-blood transcriptomics at day 0 and day 2 were analyzed using multimodal factor analysis (MEFISTO). The primary outcome was 90-day mortality, with validation in an independent critically ill sepsis cohort (EARLI). RESULTS: Multiomics integration revealed 4 molecular signatures associated with mortality: (a) enhanced innate immune activation coupled with increased glycolysis (associated with hyperinflammatory phenotype), (b) hepatic dysfunction and immune dysfunction paired with impaired fatty acid β-oxidation (associated with hyperinflammatory phenotype), (c) interferon program suppression coupled with altered mitochondrial respiration (associated with hyperinflammatory phenotype), and (d) redox impairment and cell proliferation pathways (not associated with inflammatory phenotype). These signatures persisted through day 2 of trial enrollment. Within-phenotype analysis revealed distinct mortality-associated pathways in each group. All molecular signatures were validated in the independent EARLI cohort. CONCLUSION: Inflammatory phenotypes of ARDS reflect distinct underlying biological processes with both phenotype-specific and phenotype-independent pathways influencing patient outcomes, all characterized by mitochondrial dysfunction. These findings suggest potential therapeutic targets for precise treatment strategies in critical illness. FUNDING: NIH National Heart, Lung, and Blood Institute and National Institute of General Medical Sciences.


  • Open Access

    Minimalistic transcriptomic signatures permit accurate early prediction of COVID-19 mortality

    by Rithwik Narendra, Emily C. Lydon, Hoang Van Phan, Natasha Spottiswoode, Lucile P. Neyton, Joann Diray-Arce, Impacc Network, Patrice M. Becker, Seunghee Kim-Schulze, Annmarie Hoch, et al.

    BACKGROUND: Accurate prognostic assays for COVID-19 represent an unmet clinical need. We sought to identify and validate early parsimonious transcriptomic signatures that accurately predict fatal outcomes. METHODS: We studied 894 patients enrolled in the prospective, multicenter Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) with peripheral blood mononuclear cells (PBMC) and nasal swabs collected within 48 hours of admission. Host gene expression was measured with RNA-Seq. We trained parsimonious prognostic classifiers incorporating host gene expression, age, and SARS-CoV-2 viral load to predict 28-day mortality in 70% of the cohort. Classifier performance was determined in the remaining 30% and externally validated in a contemporary COVID-19 cohort ( n = 137) with vaccinated patients. RESULTS: Fatal COVID-19 was characterized by 4,189 differentially expressed genes in the peripheral blood. A COVID-specific 3-gene peripheral blood classifier ( CD83 , ATP1B2 , DAAM2 ) combined with age and SARS-CoV-2 viral load achieved an area under the receiver operating characteristic curve (AUC) of 0.88 (95% CI, 0.82–0.94). A 3-gene nasal classifier ( SLC5A5 , CD200R1 , FCER1A ), in comparison, yielded an AUC of 0.74 (95% CI, 0.64–0.83). Notably, OLAH , the most strongly upregulated gene in both PBMC and nasal swab and recently implicated in severe viral infection pathogenesis, yielded AUCs of 0.86 (0.79–0.93) and 0.78 (95% CI, 0.69–0.86), respectively. Both peripheral blood classifiers demonstrated comparable performance in an independent contemporary cohort of vaccinated patients (AUCs 0.74–0.80). CONCLUSION: Our parsimonious blood- and nasal-based classifiers accurately predicted COVID-19 mortality and merit further study as accessible prognostic tools to guide triage, resource allocation, and early therapeutic interventions. FUNDING: NIH: 5R01AI135803-03, R35HL140026, 5U19AI118608-04, 5U19AI128910-04, 4U19AI090023-11, 4U19AI118610-06, R01AI145835-01A1S1, 5U19AI062629-17, 5U19AI057229-17, 5U19AI125357-05, 5U19AI128913-03, 3U19AI077439-13, 5U54AI142766-03, 5R01AI104870-07, 3U19AI089992-09, 3U19AI128913-03, 5T32DA018926-18, and K0826161611. National Institute of Allergy and Infectious Diseases, NIH: 3U19AI1289130, U19AI128913-04S1, and R01AI122220. National Center for Advancing Translational Sciences, NIH: UM1TR004528. The National Science Foundation: DMS2310836. The Chan Zuckerberg Biohub San Francisco.


  • Open Access

    EquiOx: A Prospective study of pulse oximeter bias and skin pigmentation in critically-ill adults

    by Carolyn M. Hendrickson, Michael S. Lipnick, David Chen, Danni Chen, Tyler J. Law, Romain Pirracchio, John R. Feiner, Ella Behnke, Yu (Celine) Chou, Seif Elmankabadi, et al.

    Rationale: Pulse oximeter performance may vary by skin pigmentation, but most data are retrospective with key limitations. Objective: To quantify pulse oximeter bias [mean difference between pulse oximeter oxygen saturation (SpO 2 ) and arterial blood functional oxygen saturation (SaO 2 )], and average root mean square error (A RMS ) and estimate adjusted effects of skin pigment on bias or A RMS in critically-ill adults Methods: Prospective single-center study of 631 ICU patients (2022–2024) directly observed SpO and SaO pairs. Skin pigment was assessed using the subjective Monk Skin Tone Scale and objective spectrophotometry measurement (Individual Typology Angle [ITA]). Adjusted effects were estimated with targeted maximum likelihood estimation. Main Results: Among 1,760 paired measurements from 631 critically-ill adults, median SaO 2 was 98% (IQR 96%, 99%) with 40 episodes of stable hypoxemia (SpO 2 2 systematically underestimated SaO 2 [median bias= −1.70 IQR (−2.84, −0.50)]. Bias was less negative in patients with darker skin (ITA <-30°) [−1.05 (−2.44, −0.10)] vs lighter skin (ITA >30°) [−2.01 (−3.34, −1.00)] and remained significantly different in adjusted analyses. A RMS was 3.87 (95% CI 3.25, 4.53) overall and 4.49 (95% CI 2.63, 7.07) in patients with darker skin. Ear probes performed worse than finger probes [bias: −2.20 vs. −1.60; A RMS : 4.90 vs. 2.70]. Conclusions: In this large ICU cohort, hypoxemia was rare, pulse oximeters systematically underestimated SaO, performance varied by skin pigment and probe site. Bias was less negative in patients with darker skin. Pulse oximeter inaccuracies in ICU patients may be more substantial than clinicians recognize. Key Points: Question: Does pulse oximeter bias in critically-ill adults differ by skin pigmentation? Findings: In this prospective, single-center study of 631 critically-ill adults, oximeter mean bias was negative for all patients but relatively less negative for patients with darker pigment. Bias variation by pigment was nonlinear and larger in ear than finger probes. Meaning: Pulse oximeter bias varies with skin pigmentation and may not always be positive in patients with darker pigmentation. Pulse oximeter inaccuracy may be larger than clinicians appreciate. Additional studies with multiple oximeter brands and more stable hypoxemia are needed to further understand bias variation with skin pigment.


  • Open Access

    Microbial dynamics and pulmonary immune responses in COVID-19 secondary bacterial pneumonia

    by Natasha Spottiswoode, Alexandra Tsitsiklis, Victoria T. Chu, Hoang Van Phan, Catherine DeVoe, Christina Love, Rajani Ghale, Joshua Bloomstein, Beth Shoshana Zha, Cole P. Maguire, et al.

    Secondary bacterial pneumonia (2°BP) is associated with significant morbidity following respiratory viral infection, yet remains incompletely understood. In a prospective cohort of 112 critically ill adults intubated for COVID-19, we comparatively assess longitudinal airway microbiome dynamics and the pulmonary transcriptome of patients who developed 2°BP versus controls who did not. We find that 2°BP is significantly associated with both mortality and corticosteroid treatment. The pulmonary microbiome in 2°BP is characterized by increased bacterial RNA mass and dominance of culture-confirmed pathogens, detectable days prior to 2°BP clinical diagnosis, and frequently also present in nasal swabs. Assessment of the pulmonary transcriptome reveals suppressed TNFα signaling in patients with 2°BP, and sensitivity analyses suggest this finding is mediated by corticosteroid treatment. Further, we find that increased bacterial RNA mass correlates with reduced expression of innate and adaptive immunity genes in both 2°BP patients and controls. Taken together, our findings provide fresh insights into the microbial dynamics and host immune features of COVID-19-associated 2°BP, and suggest that suppressed immune signaling, potentially mediated by corticosteroid treatment, permits expansion of opportunistic bacterial pathogens.


  • Open Access

    Immediate myeloid depot for SARS-CoV-2 in the human lung

    by Mélia Magnen, Ran You, Arjun A. Rao, Ryan T. Davis, Lauren Rodriguez, Olivier Bernard, Camille R. Simoneau, Lisiena Hysenaj, Kenneth H. Hu, Mazharul Maishan, et al.

    In the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, epithelial populations in the distal lung expressing Angiotensin-converting enzyme 2 (ACE2) are infrequent, and therefore, the model of viral expansion and immune cell engagement remains incompletely understood. Using human lungs to investigate early host-viral pathogenesis, we found that SARS-CoV-2 had a rapid and specific tropism for myeloid populations. Human alveolar macrophages (AMs) reliably expressed ACE2 allowing both spike-ACE2–dependent viral entry and infection. In contrast to Influenza A virus, SARS-CoV-2 infection of AMs was productive, amplifying viral titers. While AMs generated new viruses, the interferon responses to SARS-CoV-2 were muted, hiding the viral dissemination from specific antiviral immune responses. The reliable and veiled viral depot in myeloid cells in the very early phases of SARS-CoV-2 infection of human lungs enables viral expansion in the distal lung and potentially licenses subsequent immune pathologies.


  • Open Access

    Distinct pulmonary and systemic effects of dexamethasone in severe COVID-19

    by Lucile P A Neyton, Ravi K Patel, Aartik Sarma, UCSF COMET Consortium, Andrew Willmore, Sidney C Haller, Kirsten N Kangelaris, Walter L Eckalbar, David J Erle, Matthew F Krummel, et al.

    Dexamethasone is the standard of care for critically ill patients with COVID-19, but the mechanisms by which it decreases mortality and its immunological effects in this setting are not understood. Here we perform bulk and single-cell RNA sequencing of samples from the lower respiratory tract and blood, and assess plasma cytokine profiling to study the effects of dexamethasone on both systemic and pulmonary immune cell compartments. In blood samples, dexamethasone is associated with decreased expression of genes associated with T cell activation, including TNFSFR4 and IL21R. We also identify decreased expression of several immune pathways, including major histocompatibility complex-II signaling, selectin P ligand signaling, and T cell recruitment by intercellular adhesion molecule and integrin activation, suggesting these are potential mechanisms of the therapeutic benefit of steroids in COVID-19. We identify additional compartment- and cell- specific differences in the effect of dexamethasone that are reproducible in publicly available datasets, including steroid-resistant interferon pathway expression in the respiratory tract, which may be additional therapeutic targets. In summary, we demonstrate compartment-specific effects of dexamethasone in critically ill COVID-19 patients, providing mechanistic insights with potential therapeutic relevance. Our results highlight the importance of studying compartmentalized inflammation in critically ill patients.


  • Open Access

    Elevated Hemoglobin A1c and the Risk of Developing ARDS in Two Cohort Studies

    by Avery M. Bogart, Christine R. Lopez, Sarah N. Obeidalla, Chunxue Wang, Andrew Willmore, Alejandra Jauregui, Kirsten N. Kangelaris, Carolyn Hendrickson, Antonio Gomez, Kathleen D. Liu, et al.


  • Open Access

    Safety and Efficacy of Disulfiram in Hospitalized Patients with Moderate COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial

    by Augusto Cesar Mota, Valdir C. Sant’ana Filho, Carolyn M. Hendrickson, Rachel M. DeVay, Matt Donne, An M. Nguyen, Caroline Junqueira, Mark Marino, Munish Mehra, Ransi Somaratne, et al.

    OBJECTIVES: Disulfiram, a low-cost generic drug used for alcohol dependence, holds the potential to mitigate disease progression in patients with moderate COVID-19 by targeting inflammasomes. This study aimed to evaluate the clinical efficacy and safety of disulfiram when administered alongside standard of care for the treatment of hospitalized individuals with moderate COVID-19. DESIGN: A randomized, double-blind, placebo-controlled trial. SETTING: Conducted at four clinical sites in Brazil between December 2020 and August 2021. PARTICIPANTS: 140 participants aged 35 and older with laboratory-confirmed SARS-CoV-2 infection, hospitalized for ≤5 days with moderate symptoms of COVID-19 were enrolled, 137 were randomized. INTERVENTION: Participants were randomized in a 1:1 ratio to receive a daily dose of 500 mg of disulfiram (N=68) or placebo (N=69) for 14 days while receiving the current standard of care. Randomization was stratified by age and comorbidities (hypertension, diabetes, and BMI ≥35). MEASUREMENTS AND MAIN RESULTS: The primary outcome, median time to clinical improvement [95% CI] did not significantly differ between groups (disulfiram: 3.5 [3.00, 4.00] days; placebo: 4 [3.00, 5.00] days; P=.73). Key secondary outcomes, such as mean days (SD) on supplemental oxygen [disulfiram: 4.4 (6.61) days; placebo: 3.7 (5.80) days, P=.34], median (95% CI) time to hospital discharge [disulfiram: 6.0 (5.00, 8.00) days, placebo: 5.0 (4.00, 7.00)], proportion of participants discharged by day 8 [disulfiram (68%), placebo (63%), odds ratio: 0.801], and proportion of participants who clinically worsened [disulfiram (21%), placebo (19%), P=.79], did not reveal significant differences. While the incidence of adverse events was higher in the disulfiram group, serious adverse events and 28-day mortality were comparable between the two groups. Conclusions: Although disulfiram was found to be safe in hospitalized patients with moderate COVID-19, it did not shorten the time to clinical improvement. These findings do not support the use of disulfiram alongside standard of care in this patient population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04594343 Key Points: Background: Disulfiram has been proposed to mitigate disease progression in patients with COVID-19 by targeting the inflammasomes. Question: Does disulfiram, a generic drug used for alcohol use disorder, reduce the time to clinical improvement or reduce the risk of severe disease in hospitalized patients with moderate COVID-19 and with comorbidities when added to the standard of care? Findings: In this double-blind, placebo-controlled randomized clinical trial of adults hospitalized with moderate COVID-19 in Brazil, the addition of an oral disulfiram treatment to the standard of care was safe. Still, it did not decrease the time to clinical improvement. Meaning: The study findings do not support the use of disulfiram in hospitalized patients with moderate COVID-19 in addition to the standard of care.


  • Open Access

    Early plasma angiopoietin-2 is prognostic for ARDS and mortality among critically ill patients with sepsis

    by Carrie M. Rosenberger, Katherine D. Wick, Hanjing Zhuo, Nelson Wu, Yue Chen, Sharookh B. Kapadia, Alessander Guimaraes, Diana Chang, David F. Choy, Hubert Chen, et al.

    Angiopoietin-2 (Ang-2) is associated with vascular endothelial injury and permeability in the acute respiratory distress syndrome (ARDS) and sepsis. Elevated circulating Ang-2 levels may identify critically ill patients with distinct pathobiology amenable to targeted therapy. We hypothesized that plasma Ang-2 measured shortly after hospitalization among patients with sepsis would be associated with the development of ARDS and poor clinical outcomes. To test this hypothesis, we measured plasma Ang-2 in a cohort of 757 patients with sepsis, including 267 with ARDS, enrolled in the emergency department or early in their ICU course before the COVID-19 pandemic. Multivariable models were used to test the association of Ang-2 with the development of ARDS and 30-day morality. We found that early plasma Ang-2 in sepsis was associated with higher baseline severity of illness, the development of ARDS, and mortality risk. The association between Ang-2 and mortality was strongest among patients with ARDS and sepsis as compared to those with sepsis alone (OR 1.81 vs. 1.52 per log Ang-2 increase). These findings might inform models testing patient risk prediction and strengthen the evidence for Ang-2 as an appealing biomarker for patient selection for novel therapeutic agents to target vascular injury in sepsis and ARDS.